|
Cardium Therapeutics chooses OmniComm Systems Inc. Over Competing EDC Vendors
as its Web-Based Data Collection and Management Solution
Forward-focused medical technology company chooses OmniComm’s client intuitive
TrialMasterTMEDC solution for a Phase 3 multi-site cardiovascular therapeutic
study for women
FT. LAUDERDALE, FL – April 2, 2007 – /MarketWire/ - OmniComm Systems,
Inc. (OTC Bulletin Board: OMCM.OB), one of the fastest growing companies in the
EDC marketplace, today announced that Cardium Therapeutics of San Diego, CA has
selected the TrialMaster EDC solution for conducting a Phase 3 study in women which
will evaluate Generx™ (alferminogene tadenovec) as a potential treatment for
myocardial ischemia (insufficient blood flow within the heart muscle).
Generx is considered the first and only DNA-based cardiovascular therapeutic to
be advanced to Phase 3 and is believed to be the only current Phase 3 product candidate
for stable angina, a chronic medical condition affecting millions of patients in
the U.S. and worldwide. “During a clinical trial there can be significant
challenges in getting trial data when you want it and in the format that you need
it,” said Anthony Andrasfay, Vice President of Clinical Operations for Cardium.
“The TrialMaster EDC solution provides us with an intuitive and easy to use
export tool that simplifies the process. Integration is also very important to us
and with the TrialMaster solution we’ve been able to easily integrate with
our IVRS solution to manage enrollment and randomization.”
OmniComm’s TrialMaster is an easy to use and flexible web-based EDC and trial
management solution. Clients like Cardium can benefit from the feature-rich functionality
inherent in TrialMaster. And they can conduct their clinical trials more effectively
using software and services that optimize the efficiency and accuracy of data collection,
while reducing the costs associated with paper-based clinical trials.
“It is a tribute to OmniComm’s dedication to providing unmatched customer
focused EDC solutions that Cardium has chosen TrialMaster for their data management
needs,” said Cornelis F. Wit, President and CEO of OmniComm. Our team is proud
to be partnering with Cardium as they work to bring breakthrough products to the
marketplace. Our TrialMaster solution provides companies such as Cardium with a
flexible and cost effective solution to securely collect, validate, analyze and
transmit clinical study data.”
About Cardium
Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies and the Tissue
Repair Company, are medical technology companies primarily focused on the development,
manufacture and sale of innovative therapeutic products and devices for cardiovascular,
ischemic and related indications. For more information about Cardium and its businesses,
products and therapeutic candidates, please visit www.cardiumthx.com or view its brochure at http://www.cardiumthx.com/flash/pdf/CardiumTHX_
Brochure.pdf and its filings with the Securities and Exchange Commission.
About OmniComm
OmniComm Systems, Inc. provides customer-driven Internet solutions to pharmaceutical,
biotechnology, research and medical device organizations that conduct life changing
clinical trial research. OmniComm’s growing base of satisfied customers is
a direct result of the company’s commitment to deliver products and services
that ensure ease of use, faster study build, ease of integration and better performance.
OmniComm’s intuitive pricing model allows companies that range from small
to mid-size to large scale institutions to safely and efficiently capitalize on
their clinical research investments.
OmniComm is ranked in the top 150 as one of the fastest revenue growth technology
companies in North America during the last 5 years. In a market overview titled
“The Promise of Next-Gen eClinical Trial Software” by Forrester Research;
OmniComm was given the highest rating among its competitors for industry middleware.
OmniComm Systems Inc. has corporate headquarters in Ft. Lauderdale, Florida with
offices in California, Maryland, New Jersey, North Carolina, Texas and The Netherlands.
Safe Harbor Disclaimer
Statements about OmniComm’s future expectations, including without limitation,
future revenues and earnings, plans and objectives for the future operations, future
agreements, future economic performance, operations and all other statements in
this press release other than historical facts are "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933, Section 21E of
the Securities Exchange Act of 1934, and as that term is defined in the Private
Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking
statements be subject to the Safe Harbors created thereby. Since these statements
involve risks and uncertainties, including but not limited to economic competitive,
governmental, contractual and technological factors affecting OmniComm’s operations,
markets and profitability, actual results could differ materially and adversely
from the expected results.
For more info, please contact Lizanne Kelley, OmniComm Systems, Inc.
954-473-1254 Extension 283, lkelley@omnicomm.com.
Back
|
